RxDoctor Payments Data

Richard Tu, MD

Internal Medicine · Falls Church, VANPI 1104937358

Payments from drug & device makers

$7,946in general payments, 2019–2025

Across 316 payments — averaging $25.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Boehringer Ingelheim$695
  • Amgen$658
  • Novo Nordisk$633
  • Lilly USA, LLC$572
  • Gilead$537
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$7,938100%
  • Education$80%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,946 in reported general payments places this provider in the 90th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$60,722
Medicare patients
88
Services billed
907

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol52$65,139
JardianceEmpagliflozin30$48,349
TrulicityDulaglutide13$27,727
EliquisApixaban17$27,444
ProliaDenosumab14$24,127
OzempicSemaglutide15$15,888
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$15,224
VascepaIcosapent Ethyl25$15,186
Rosuvastatin Calcium403$4,743
Clobetasol Propionate33$1,823
Amlodipine Besylate233$1,451
Olmesartan Medoxomil103$1,349
Diclofenac Sodium18$1,340
Fluticasone Propionate117$1,284
Metoprolol Succinate123$1,132

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$2,238$65,13952 claims
Boehringer IngelheimJardiance$695$48,34930 claims
Lilly USA, LLCTrulicity$572$27,72713 claims
PfizerEliquis$466$27,44417 claims
AmgenProlia$658$24,12714 claims
Novo NordiskOzempic$633$15,88815 claims
GSKTrelegy Ellipta$252$15,22420 claims
Teva Pharmaceuticals USA, Inc.Acyclovir$31$35814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Falls Church

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →